Clinical trials
Interstitial Lung Disease Due to Systemic Disease clinical trials
Below are recruiting interstitial lung disease due to systemic disease clinical trials, each written for real people, not researchers. We’re tracking 36 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05798923RecruitingPhase 2
LAM-001 for lung scarring with high blood pressure
This trial tests a new medication called LAM-001 for people with high blood pressure in the lungs caused by lung scarring. It aims to see if it can improve symptoms and help you feel better.
Tucson, ArizonaAges 18–80 - NCT05365009Recruiting
Autoimmune lung scarring registry for adults with recent diagnosis
This registry collects health and breathing test information from adults with autoimmune-related lung scarring (interstitial lung disease) diagnosed recently. It helps researchers better understand who has this condition and how it changes over time.
Buenos AiresAges 18 years+ - NCT05785065RecruitingPhase 2
Mycophenolate for early lung scarring in systemic sclerosis
This Phase 2 study tests whether mycophenolate mofetil (MMF) can slow or improve early, mild lung scarring in people with systemic sclerosis. It’s meant for systemic sclerosis patients who have lung involvement on a CT scan but still have good breathing test results.
Montreal, QuebecAges 18 years+ - NCT05878717RecruitingPhase 2/Phase 3
Belimumab for adults with scleroderma lung scarring
This Phase 2/3 study tests whether belimumab can improve outcomes and safety in adults with systemic sclerosis (scleroderma) that has caused lung scarring. It may help by reducing active or worsening immune-driven disease in the lungs.
Phoenix, ArizonaAges 18 years+ - NCT06195072RecruitingPhase 2
Platform study for scleroderma with lung disease
This trial tests new treatments for people with scleroderma-related lung disease. You may be eligible if you have systemic sclerosis with lung scarring, your symptoms started within the last 7 years, and you have not had certain prior treatments or transplants.
Birmingham, AlabamaAges 18 years+ - NCT06696027Recruiting
Loss of Y chromosome in autoimmune and lung disease
This study looks at how the loss of the Y chromosome in blood cells may be linked to autoimmune and lung diseases in older men. By joining, you help researchers understand this connection better.
Bonn, North Rhine-WestphaliaAges 50 years+ - NCT06716606RecruitingPhase 3
Long-term safety of belimumab for lung disease in scleroderma and other connective tissue diseases
This study tests the long-term safety and effectiveness of belimumab for people with lung scarring caused by scleroderma or other connective tissue diseases. It is for patients who already completed a one-year study with belimumab and were not considered treatment failures.
Philadelphia, PennsylvaniaAges 18 years+ - NCT06817590RecruitingPhase 1
Nucleoside therapy for telomere disorders
This trial tests a nucleoside therapy (dC/dT) for people with telomere biology disorders, which cause premature aging and problems like low blood counts, lung or liver issues. The goal is to see if the treatment can help manage these symptoms.
Boston, MassachusettsAges 1–70 - NCT07174102Recruiting
Looking at lung scans in rheumatoid arthritis and related diseases
This trial studies lung scans (HRCT) from patients with rheumatoid arthritis, interstitial lung disease, or connective tissue disease to better understand lung involvement. If you have one of these conditions and have had a lung CT, you may be able to help.
PragueAges 18 years+ - NCT07323732RecruitingPhase 2
BIO 300 and radiation for lung cancer with lung scarring
This trial tests if adding BIO 300 to chest radiation is safe and helps people who have both non-small cell lung cancer (early stage) and interstitial lung disease (scarring of the lungs). It aims to find better treatment options for this specific group.
Basking Ridge, New JerseyAges 18 years+ - NCT07345052Recruiting
Study on systemic sclerosis in western Sweden
This study is looking at people with systemic sclerosis (a condition that causes hardening and tightening of the skin and can affect internal organs) to learn more about the disease. You may join if you have been diagnosed with this condition and meet a few other requirements.
Gothenburg, SwedenAges 18 years+ - NCT07061873Enrolling by invitation
Exercise program for adults with lung disease
This study tests a physical exercise program designed for adults with diffuse interstitial lung disease. It aims to help improve your breathing and daily function through supervised exercise in a pulmonary rehabilitation setting.
Temuco, CautínAges 18 years+ - NCT07572383RecruitingPhase 2
Imaging Study of Immunosuppression for Progressive Lung Fibrosis
This study uses advanced imaging to see how immunosuppressive medications (like mycophenolate or prednisone) affect lung scarring in patients with certain types of lung fibrosis. You would have imaging scans and breathing tests to track changes over time.
Boston, MassachusettsAges 18–80 - NCT06428188RecruitingPhase 1/Phase 2
CAR-T cells targeting BCMA/CD19 for autoimmune diseases
This trial tests a new treatment called CAR-T cells that target two proteins (BCMA and CD19) on immune cells. It is for people with certain autoimmune diseases that have not improved with standard treatments.
Beijing, Beijing MunicipalityAges 21–90 - NCT07246096RecruitingEarly Phase 1
CAR-T cell therapy for autoimmune diseases
This trial tests a new CAR-T cell treatment for people with certain autoimmune diseases that have not responded to standard therapies. The treatment uses your own immune cells modified to target and attack disease-causing cells.
ShanghaiAges 18–70 - NCT06375993Enrolling by invitationPhase 1
Prula-cel for autoimmune diseases: a phase 1 study
This trial tests a new treatment called prulacabtagene leucel (prula-cel), which is a type of immune cell therapy (CAR T-cells) for people with certain autoimmune diseases. It aims to see if it can reset the immune system and reduce disease activity in conditions like lupus, scleroderma, vasculitis, or myositis.
Redwood City, CaliforniaAges 18–80 - NCT06941129RecruitingPhase 1
CAR T-cell therapy for resistant autoimmune diseases
This trial tests a new type of immune therapy called CAR T-cells that target two markers on your B cells (CD19 and BCMA). It is for people with certain autoimmune diseases that have not improved or have come back after standard treatments. The goal is to see if this therapy can help control the disease.
TianjinAges 18 years+ - NCT07236801RecruitingPhase 1
Cell therapy for hard-to-treat autoimmune diseases
This trial tests a new cell therapy called YTS109 for people with several autoimmune diseases that have not improved with standard medications. It aims to see if this treatment can help control the disease when other treatments have failed.
Xuzhou, JiangsuAges 18–65 - NCT07526350RecruitingEarly Phase 1
MTS109 for Hard-to-Treat Autoimmune Diseases
This early-stage trial tests a new treatment called MTS109 for autoimmune diseases (like lupus, muscle inflammation, scleroderma, vasculitis, or Sjögren's syndrome) that haven't responded well to standard medications. The goal is to see if MTS109 can help control disease that keeps flaring or getting worse despite current treatments.
Shanghai, Shanghai MunicipalityAges 18–65 - NCT06708845RecruitingPhase 1
Zamto-cel cell therapy for autoimmune diseases
This early-phase trial tests a new cell therapy called Zamto-cel for people with lupus (with or without kidney inflammation) or systemic sclerosis (hardening of the skin and internal organs). It is for those whose condition has not improved enough after standard treatments.
Milwaukee, WisconsinAges 18 years+ - NCT07315087RecruitingPhase 1
CAR T-cell therapy for autoimmune diseases
This trial tests a special type of cell therapy (CAR T-cells) that targets two markers on immune cells, CD19 and BCMA, to calm overactive immune systems in people with certain autoimmune diseases. It's for those whose disease has not been controlled by standard treatments.
TianjinAges 18 years+ - NCT07104721RecruitingPhase 1
YTS109 cell therapy for severe autoimmune diseases
This trial tests a new cell therapy called YTS109 for people with severe autoimmune diseases that have not responded to standard treatments. The goal is to see if it can reset the immune system and reduce disease activity in conditions like lupus, Sjögren's syndrome, and others.
Hefei, AnhuiAges 18–65 - NCT06888973Enrolling by invitationPhase 1/Phase 2
Stem cell infusion for autoimmune diseases
This clinical trial is testing if infusions of special stem cells (called mesenchymal stem cells) can help people with certain autoimmune diseases where standard treatments have not worked well enough. It is an early-phase study in Pakistan for adults (and some children for one condition) with rheumatoid arthritis, lupus, systemic sclerosis, ankylosing spondylitis, or dermatomyositis/polymyositis.
RawalpindiAges 18–50 - NCT07085676RecruitingPhase 1
CAR-T cell therapy for autoimmune diseases that resist treatment
This study tests a new cell therapy called CAR-T (using your own immune cells) for people with severe autoimmune diseases like lupus, scleroderma, or myositis that have not improved with standard treatments. The goal is to see if it can safely reduce disease activity.
JerusalemAges 18–80
Hear when a new Interstitial Lung Disease Due to Systemic Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for interstitial lung disease due to systemic disease?
- Yes. Clin2 currently lists 36 recruiting interstitial lung disease due to systemic disease studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a interstitial lung disease due to systemic disease trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a interstitial lung disease due to systemic disease trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Interstitial Lung Disease Due to Systemic Disease (Disorder)
- Interstitial Lung Disease
- Non Small Cell Lung Cancer
- Fibrotic Interstitial Lung Disease
- Pulmonary Hypertension Due to Lung Diseases and Hypoxia
- Lung Fibrosis Interstitial
- Rheumatoid Arthritis-Associated Interstitial Lung Disease
- Systemic Lupus Erythematosus
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.